SEC Filing Summary
Filing identity: The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2016, filed August 4, 2016. This does not match the request metadata naming Crescent BioPharma, Inc.
Business Context and Reporting Period
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. It has no approved products or commercial drug sales. Its lead programs include GMI-1271, under company development, and rivipansel, licensed worldwide to Pfizer. Financial comparisons below cover the three and six months ended June 30, 2016 versus the same periods in 2015; balance sheet comparisons are June 30, 2016 versus December 31, 2015.
Financial Highlights
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $20.04 million | $0 | $20.04 million |
| Research and development | $5.78 million | $7.84 million | $11.30 million | $13.05 million |
| General and administrative | $2.31 million | $1.81 million | $4.37 million | $3.71 million |
| Net income (loss) | $(8.07) million | $10.39 million | $(15.63) million | $3.28 million |
| Operating cash flow | Not separately provided | Not separately provided | $(16.30) million | $(14.85) million |
- At June 30, cash and cash equivalents were $53.09 million, compared with $46.80 million at year-end 2015. Current assets were $54.53 million and current liabilities $6.09 million.
- Total liabilities were $6.89 million, principally operating lease-related deferred rent and current operating liabilities; the filing reports no borrowings or debt balance.
- Six-month investing cash outflow was $0.04 million; financing cash inflow was $22.63 million. Cash increased $6.28 million during the period.
- Gross or operating margins are not meaningful because the company reported no product revenue and is a development-stage business.
Material Changes Versus Prior Period
- Revenue and earnings fell sharply because 2015 included a $20.0 million Pfizer milestone payment triggered by the first patient dosed in rivipansel’s Phase 3 trial; no milestone or royalty revenue was recorded in 2016.
- R&D expense declined 26% in Q2 and 13% for the six-month period. The main year-over-year factor was the absence of the approximately $2.0 million University of Basel milestone-related license fee recorded in 2015. Clinical development spending increased while manufacturing and formulation spending declined.
- G&A expense increased 28% in Q2 and 18% for the six-month period, mainly from personnel and stock-based compensation.
- Operating cash use increased to $16.30 million from $14.85 million for the first half. The company raised approximately $19.8 million net in a June public offering and $2.7 million net through its at-the-market program; these financings increased shares outstanding.
Outlook, Commentary, and Risks
- Management estimated existing cash would fund operating expenses and capital needs through the second quarter of 2018, while cautioning that assumptions could prove incorrect and spending could exceed expectations.
- The company expects significant expenses and operating losses to continue, with R&D spending expected to rise as GMI-1271, GMI-1359, and other programs advance. Profitability is uncertain and additional capital may be needed.
- GMI-1271’s Phase 1 AML portion enrolled 19 patients; management reported nine remissions (47% overall response rate), no dose-limiting toxicities, and no treatment-phase mortality. The Phase 2 portion began dosing in June 2016, with approximately 50 patients expected. These are company-reported trial results, not proof of efficacy.
- The company submitted an IND for GMI-1359 in June 2016 and planned to begin a Phase 1 healthy-volunteer trial in Q3 2016. A University of Michigan GMI-1271 study in calf-level deep vein thrombosis began in Q3 2016, with enrollment expected to finish in Q4.
- Pfizer’s future development, regulatory, sales milestones and royalties are contingent and uncertain. The company also owes the University of Basel 10% of specified future rivipansel milestone and royalty receipts. The lease runs through October 2023; remaining rent obligations were reported at $7.33 million.
- Key risks include clinical and regulatory failure, patient enrollment and trial costs, dependence on additional financing, dilution or unfavorable financing terms, and reliance on Pfizer for rivipansel development and commercialization. No material legal proceedings were reported; management said disclosure controls were effective and risk factors had not materially changed from the prior 10-K.
Important Facts for Investors to Verify
- Confirm the filing issuer: the source document identifies GlycoMimetics, Inc., not Crescent BioPharma, Inc.
- Check subsequent clinical-trial and regulatory disclosures for GMI-1271 and GMI-1359, including whether reported early-stage results were confirmed in later studies.
- Track cash burn, financing activity, share dilution, and whether the stated runway through Q2 2018 remained achievable.
- Verify the status and terms of Pfizer’s rivipansel program and any milestone or royalty payments, including the University of Basel’s 10% participation.